Since ALDOB typically suppresses glycolysis to exert its anticancer effects, its reduced activity in HCC could be a critical factor in tumor progression, supporting the therapeutic potential of activating ALDOB by inhibiting MRTO4 205. This evidence concerns the gene ALDOB and hepatocellular carcinoma.